Wex Pharmacetuicals
- Company typePrivate
- Founded1987
- HeadquartersVancouver, Canada
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Wex Pharmacetuicals firmographics
Firmographics- Name
- Wex Pharmacetuicals
- Website
- https://wexpharma.com
- Company type
- Private
- Founded year
- 1987
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Wex Pharmacetuicals industry classification
Industry- Product category
- Pain Management Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
- akta.pro secondary industry
- Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)
Keywords
Where Wex Pharmacetuicals is headquartered
LocationHeadquarters
- HQ city
- Vancouver
- HQ country
- Canada
- HQ region
- North America
Markets served
Wex Pharmacetuicals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Wex Pharmacetuicals product offering
Product offeringCore offering
Wex Pharmaceuticals is a biopharmaceutical company developing a late-stage non-opioid analgesic for the treatment of Chemotherapy Induced Peripheral Neuropathy (CIPN). The company is actively advancing a pipeline of 5+ candidate drugs aimed at addressing neuropathic pain, tingling, and numbness in cancer patients undergoing chemotherapy.
Product overview
Wex Pharmaceuticals is a biopharmaceutical company developing treatments for chemotherapy-induced peripheral neuropathy (CIPN). The company is among the active participants in clinical trials for new CIPN treatments alongside other companies such as AlgoTx and Asahi Kasei Pharma.
Differentiator
Problem solved
Functional benefit
Products and services
- Late-stage non-opioid analgesic for CIPN
Companies that use Wex Pharmacetuicals
Customer profileSegments2 records
Ideal customer profiles1 record
Wex Pharmacetuicals technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Wex Pharmacetuicals partnerships and signals
Strategic signalScale indicators2 records
Recent moves2 records
Expansion highlights2 records
Wex Pharmacetuicals competitors and assessment
Company assessmentDirect peers
- AlgoTx: AlgoTx is a clinical-stage biopharma developing novel treatments for CIPN and chemotherapy-induced neuropathic pain. It is explicitly cited alongside Wex Pharmaceuticals as an active CIPN trial participant, making it the closest direct peer in indication and stage.
- Asahi Kasei Pharma: Asahi Kasei Pharma is the pharmaceutical division of Asahi Kasei Corporation and is developing therapies for CIPN. It is explicitly referenced alongside Wex in current CIPN clinical development, giving it overlapping indication focus despite materially greater corporate resources.
Broad incumbents
- Vertex Pharmaceuticals: Vertex Pharmaceuticals is a leading developer of non-opioid analgesics (notably the NaV1.8 inhibitor suzetrigine/Journavx for acute pain) and is widely viewed as setting the commercial bar for non-opioid pain therapeutics, comparable in therapeutic class to Wex's non-opioid analgesic focus.
- Grünenthal: Grünenthal is a Germany-based specialty pharma with a deep focus on pain therapeutics, including neuropathic pain. It is comparable to Wex as a pain-focused specialty developer, though it operates at significantly larger scale with established commercial infrastructure.
- Eli Lilly (neuropathic pain franchise): Eli Lilly operates one of the largest neurology and pain franchises globally and is a frequent acquirer of late-stage CNS/pain assets. It represents the upper bound of comparable incumbents in the neuropathic pain therapeutic class that Wex is targeting.
- Pfizer (neuropathic pain portfolio): Pfizer markets established neuropathic pain therapies (e.g., Lyrica/Neurontin franchises) and is a benchmark large-pharma participant in the neuropathic pain space, providing indirect comparability to Wex's CIPN-focused analgesic approach.
Emerging players
- Lexicon Pharmaceuticals: Lexicon Pharmaceuticals is developing neuropathic pain therapies and is comparable to Wex as a small-cap, clinical-stage developer focused on neuropathic pain indications, though its portfolio is broader than Wex's CIPN focus.
- Aptinyx: Aptinyx is a clinical-stage biotech developing NMDA-receptor modulators for chronic pain and CNS indications, including neuropathic pain. It overlaps with Wex in pain/CNS mechanism and clinical-stage biopharma profile.
- Latigo Biotherapeutics: Latigo Biotherapeutics is a clinical-stage biopharma developing non-opioid pain therapeutics targeting sodium channels. It is comparable to Wex as a focused, clinical-stage developer of non-opioid analgesics in the broader pain space.
- Chromocell Therapeutics: Chromocell Therapeutics is developing non-opioid pain treatments using its proprietary platform to identify novel analgesics. It shares Wex's positioning as a clinical-stage non-opioid pain developer, albeit in a different specific indication.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat2 records
Key risks6 records
Key highlights4 records
Customer concentration
Wex Pharmacetuicals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Wex Pharmacetuicals leadership team
Management profileNumber of profiles
Wex Pharmacetuicals funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Wex Pharmacetuicals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Wex Pharmacetuicals
What does Wex Pharmacetuicals do?
Wex Pharmaceuticals is a biopharmaceutical company developing a late-stage non-opioid analgesic for the treatment of Chemotherapy Induced Peripheral Neuropathy (CIPN). The company is actively advancing a pipeline of 5+ candidate drugs aimed at addressing neuropathic pain, tingling, and numbness in cancer patients undergoing chemotherapy.
Is Wex Pharmacetuicals a public or private company?
Wex Pharmacetuicals is a private company. It is classified as unknown and is currently operating.
When was Wex Pharmacetuicals founded?
Wex Pharmacetuicals was founded in 1987. It employs 11 to 50 people.
Where is Wex Pharmacetuicals based?
Wex Pharmacetuicals is headquartered in Vancouver, Canada, in the North America region.
Who are Wex Pharmacetuicals's main competitors?
Direct peers on record are AlgoTx and Asahi Kasei Pharma. Broad incumbents are Vertex Pharmaceuticals, Grünenthal, Eli Lilly (neuropathic pain franchise) and Pfizer (neuropathic pain portfolio). Emerging players are Lexicon Pharmaceuticals, Aptinyx, Latigo Biotherapeutics and Chromocell Therapeutics.
Does Wex Pharmacetuicals have an API?
No public API is recorded for Wex Pharmacetuicals.
What industry is Wex Pharmacetuicals in?
Wex Pharmacetuicals's product category is Pain Management Pharmaceuticals. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.